UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.148

Sortiert nach

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Link zum Volltext

Verfügbarkeit prüfen

High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab

Annals of oncology, 2023-11, Vol.34 (11), p.1064-1065

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Annals of oncology, 2007-02, Vol.18 (2), p.317-323

2007

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Annals of oncology, 2018-10, Vol.29, p.viii740-viii740

2018

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1137-1147

2021

Link zum Volltext

Verfügbarkeit prüfen

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S152-S152

2016

Link zum Volltext

Verfügbarkeit prüfen

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

Annals of oncology, 2016-01, Vol.27 (1), p.185-192

2016

Link zum Volltext

Verfügbarkeit prüfen

Technical efficiency in dairy farms conducting educational tourism: an approach by stochastic frontier production function

International journal of sustainable development and planning, 2016-07, Vol.11 (3), p.458-468

Ohe, Y.

2016

Link zum Volltext

Verfügbarkeit prüfen

Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study

Japanese journal of clinical oncology, 2014-04, Vol.44 (4), p.346-354

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Annals of oncology, 2023-02, Vol.34 (2), p.173-185

2023

Link zum Volltext

Verfügbarkeit prüfen

Correlation between intraoperative proximal segment rotation and post-sagittal split ramus osteotomy relapse: a three-dimensional cone beam computed tomography study

International journal of oral and maxillofacial surgery, 2018-05, Vol.47 (5), p.613-621

2018

Link zum Volltext

Verfügbarkeit prüfen

Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)

Annals of oncology, 2012-09, Vol.23 (9), p.2253-2258

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety profile and effectiveness of alectinib in the real-world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29, p.viii502-viii502

2018

Link zum Volltext

Verfügbarkeit prüfen

Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): Consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii542-viii543

2018

Link zum Volltext

Verfügbarkeit prüfen

Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody

Annals of oncology, 2018-11, Vol.29, p.ix165-ix165

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-11, Vol.29, p.ix160-ix161

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases

ESMO open, 2023-08, Vol.8 (4), p.101594-101594, Article 101594

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance

Annals of oncology, 2018-10, Vol.29, p.viii431-viii432

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical courses of patients with small cell lung cancer after complete resection followed by adjuvant chemotherapy

Annals of oncology, 2018-11, Vol.29, p.ix141-ix141

2018

Link zum Volltext

Verfügbarkeit prüfen

Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients

Annals of oncology, 2018-11, Vol.29, p.ix23-ix23

2018

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Annals of oncology, 2019-10, Vol.30, p.v914-v915

2019

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Annals of oncology, 2018-11, Vol.29, p.ix150-ix150

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses

Pharmazie, 2021-06, Vol.76 (6), p.266-271

2021

Link zum Volltext

Verfügbarkeit prüfen

Tumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii509-viii509

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(909)
Mit Volltextzugriff
(959)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(526)
Humans
(439)
Life Sciences & Biomedicine
(419)
Male
(320)
Female
(275)
Middle Aged
(243)
Biological And Medical Sciences
(226)
Aged
(194)
Medical Sciences
(192)
Adult
(191)
Oncology
(144)
Animals
(126)
Physical Sciences
(103)
Lung Neoplasms - Drug Therapy
(92)
Pharmacology. Drug Treatments
(84)
Chemistry
(81)
Cardiovascular System & Cardiology
(67)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(64)
Cardiac & Cardiovascular Systems
(60)
Aged, 80 And Over
(55)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

Technical efficiency in dairy farms conducting educational tourism: an approach by stochastic frontier production function

Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Correlation between intraoperative proximal segment rotation and post-sagittal split ramus osteotomy relapse: a three-dimensional cone beam computed tomography study

Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)

Safety profile and effectiveness of alectinib in the real-world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer

Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): Consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)

Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody

Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases

Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance

Clinical courses of patients with small cell lung cancer after complete resection followed by adjuvant chemotherapy

Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses

Tumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)

Suchergebnisse filtern